A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction.
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Valsartan (Primary) ; Amlodipine
- Indications Essential hypertension; Hypertension; Left ventricular dysfunction
- Focus Therapeutic Use
- Acronyms EXCEED
- Sponsors Novartis
- 09 Mar 2011 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
- 01 Feb 2010 Results published in Hypertension.
- 22 Dec 2008 Planned number of patients addede (193) as reported by ClinicalTrials.gov.